Author: Michael A. Robinson, Money Morning

Here are three names from three different fields that could beat the overall market.

It holds the companies that belong in every portfolio’s “dividend payers” segment.

Although it’s more than doubled the S&P’s return since March, there’s still unlimited upside.

I’ve recommended this company time and time again, and it’s NEVER disappointed — doubling our money in the last year alone. If anyone is going to deliver the convenient, cashless future we’ve been hearing about for decades, it’ll be this company.

In short, there is no better, easier, safer way to position yourself for the tsunami of biotech profits that’s arriving right now than with this ETF…